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Recently, jawbone osteonecrosis has been largely reported as a potential adverse effect of bisphosphonate (BP)
administration. Because of the peculiar pharmacokinetic and pharmacodynamic features of the BF (mainly for
i.v. administration), their efficacy and large use, some major issues have to be taken into account extendedly
both by oncologists and by dentists: 1) therapeutic dental protocol for patients with diagnosis of bisphosphonate-
related osteonecrosis of the jaw (BRONJ); 2) dental strategies for patients in former or current i.v. BF treatment and in
absence of BRONJ signs; 3) strategies for patients before i.v. BF treatment. Clinical features and guidelines for the
management of this condition have been investigated and reported, sometimes with unclear indications; hence, on the
basis of the literature and our clinical experience, major end points of this paper are providing our run protocols for the
issues above described and, finally, focusing on a crucial, but not extensively investigated point: the early and correct
diagnosis of BRONJ versus metastatic jaw lesions in cancer patients.
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introduction
Osteonecrosis of the jaws has been recently recognized as
a potential complication of BF treatment [1–12], mainly by
i.v. regimen, for malignancy-associated hypercalcemia and
prevention of bone fractures in patients with metastatic bone
disease or multiple myeloma [13–15]. With regard to the social
impact and limitedly to the underestimated cumulative
incidence, as taken from retrospective studies among patients
receiving i.v. BF, it has been calculated a range from 0.8% to
12% [8, 16]. Pathogenetic mechanisms of this condition are not
completely understood and management of affected patients is
mostly on the basis of the clinical guidelines drawn from expert
opinions and case series analysis [17, 18]. Among amino-
bisphosphonates, pamidronate and zoledronate have shown the
most consistent effects for the treatment of bone metastases in
cancer, with zoledronate being more potent in vitro than
pamidronate [19]. Amino-bisphosphonates inhibit osteoclasts
at different stages, binding selectively to hydroxyapatite and
accumulating in sites of active bone remodeling. Once BF are
stored in bone, their release is dependent on the rate of bone
remodeling [20]. In addition, amino-bisphosphonates have
antiangiogenic properties both in vitro and in vivo. Clinically,
these lesions appear as nonhealing-exposed bone areas, which
can be accompanied by fistulization, purulent discharge and
pain. The current nomenclature for bisphosphonate-related
osteonecrosis of jawbone (BRONJ) lesions reflects the
prevailing hypothesis that such a condition is a form of
osteonecrosis. The need for a higher level of scientific evidence
has been already underlined [3]. In fact, the pathogenesis of
jawbone disease in patients receiving BF is largely unknown and
the biological mechanisms by which BF are responsible for
bone remodeling and angiogenesis impairment in human jaws
are still uncertain.
Risk factors for BRONJ occurrence are usually grouped in
three great categories: (i) drug-related risk factors, (ii) local risk
factors, and (iii) demographic/systemic risk factors as
extensively reported [16–21]; furthermore, other factors have
been recently thought to be linked, such as corticosteroids,
thalidomide, diabetes, smoking, alcohol use, poor
oral hygiene and chemotherapeutic agents [22–27] (Table 1).
Because of the proven benefits of i.v. BF, their high BF half-
life [28–30] and the considerable number of prescriptions,
some major issues have to be taken into account extendedly
both by oncologists and by dentists: (1) therapeutic dental
protocol for patients with diagnosis of BRONJ, (2) dental
strategies for patients in former or current i.v. BF treatment and
in absence of BRONJ signs, and (3) strategies for patients
before i.v. BF treatment. On the basis of the literature as
providing sometimes unclear indications and our clinical
experience, major end points of this paper are providing our
protocols for the issues above described and, finally, focusing
on a crucial, but not extensively investigated point: the early
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and correct diagnosis of BRONJ versus metastatic jaw lesions in
cancer patients.
As follows, some schemes are provided about the issues 1, 2
and 3, respectively.
Issue 1: dental management of patients under treatment (or
with history of treatment) with BF presence of clinical
BRONJ lesions
1. Thorough oral examination
 Signs
-Grade of bony exposure
-Oral/skin fistulas
-Local or general swellings of the soft intraoral tissues
-Degree of dental mobility
Symptoms
-Pain
-Aesthesia/dysesthesia (e.g. numbness, feeling of a heavy jaw)
2. Appraisal of BRONJ
 Periodic clinical follow-up (1–2 months)
 X-ray of jaws every 4–6 months
 Computed tomography dental scan every 6 months
 Staging (early versus late)
3. Special investigations
 Microbiological cultures should be collected to identify
bacterial or mycological pathogens with potential to cause
secondary infections
 Halitosis evaluation (e.g. by Halimeter, OralChroma)
4. Nonsurgery therapy
 Achievement and/or maintenance of optimal periodontal
and dental health
 To avoid procedures that involve direct osseous injury to
prevent other bony exposures
 To avoid the use of vasoconstrictor associated with local
anesthetics
 To eliminate sharp edges of dental crowns, inadequate
dental prosthesis, inadequate conservative restorative
treatments to prevent other bony exposures. To settle if
required.
 To examine patients with full or partial dentures for areas of
mucosal trauma, especially along the lingual flange region
(i.e. mylohyoid ridge) and where palatal and lingual tori and
bone exostoses can be present.
 To make stable teeth with grade 1 or 2 of dental mobility
 To make conservative restorative and prosthesis treatments
 To make acrylic stents or individual trays to cover areas of
exposed bone, to protect adjacent soft tissue, to improve
comfort and to maintain therapeutic agents in situ
 In case of necessary tooth extraction (see Table 2)
5. Achievement and/or maintenance of a good oral hygiene
 Over-gingival scaling
 Instruction to oral self-hygiene
 Prescription of antiseptic rinses, such as chlorhexidine 0.12%
without alcohol (three times/day)
 Local application of fluorine
 Motivation of patients regarding the importance of good
dental hygiene
6. Patient education and reassurance about BRONJ
 Delivery of informative papers (e.g. letter to dentistry,
information for the patients)
 Instruction to avoid every elective dental or surgical
procedures involving osseous injury during the treatment
Table 1. Risk factors for the development of BRONJ
Drug-related risk factors
Potency of the bisphosphonate (zoledronate > pamidronate >
alendronate > clodronate)
Way of administration (i.v. > oral)
Duration of therapy
Local risk factors
Dentoalveolar surgery (e.g. extractions, dental implant placement,
periodontal surgery involving osseous injury, periapical surgery)
Trauma to the jaw bones
Poor oral hygiene
Periodontal disease
Inflammatory dental disease (e.g. periodontal abscesses,
dental abscesses)
Palatal and lingual tori, bony exostoses, mylohyoid ridge
Trauma from poorly fitting dentures
Alcohol and tobacco abuse
History of osteonecrosis/osteomyelitis of the jaws
History of head and neck radiotherapy (?)1
Demographic and systemic risk factors
Elderly (>65 years)
Gender: female > male (?)
Caucasian race (?)
Chronic corticosteroid therapy
Chemotherapy
Estrogenic therapy
Alcohol and cigarettes abuse
Cancer diagnosis (increased risk for multiple myeloma > breast
cancer > prostate cancer > other cancers)
Osteopenia/osteoporosis diagnosis concurrent with cancer diagnosis
Malnutrition
Diabetes
Acquired or induced immunodeficiency
Anemia and thalassemia
Coagulopathies, blood dyscrasias and vascular disorders
Hyperlipemia
Connective tissue diseases
Gauchers disease
Systemic lupus erythematous
Hypothyroidism
1AAOMS (American Association of Oral and Maxillofacial Surgeons), in
the ‘‘Position Paper on BRONJ’’, asserts that patients may be considered to
have BRONJ only if they have no history of radiation therapy to the jaws.
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with BF and at least 5 years after the cessation of
bisphosphonate therapy
 Education to periodic clinical and radiographic follow-up,
with frequency depending on seriousness of BRONJ
7. Pharmacological therapy
 Broad-spectrum antibiotic therapy before antibiotic assay
according to the regimens described in Table 2
 Antifungals, if required, should be prescribed
 If patient refers pain, systemic analgesics should be prescribed
in order to mitigate symptoms
8. Surgery therapy in case of exposed/necrotic bone
 Debridement and/or sequestrectomy less traumatic as
possible, also by means of piezosurgery [31–38]
 To avoid the use of vasoconstrictor associated with local
anesthetics
 Resection of the affected bony tissue, less traumatic as
possible, also by means of piezosurgery [31–38]
 Partial, marginal or segmental resection, eventually followed
by a reconstructive therapeutic phase
9. Alternative therapy in case of exposed/necrotic bone
 Low-level laser therapy using He-Ne or diode laser.
Issue 2: dental management of patients under treatment (or
with history of treatment) with i.v. and oral BF (for oral
BF duration of therapy >3 years)—no clinical lesions
1. Early diagnosis of early stage BRONJ
 Compilation of case history paper
 Clinical follow-up (every 3–4 months)
 X-ray of jaws every 6 months
 Prescription of computed tomography dental scan when
X-ray is doubtful
 Prescription of bony scintigraphy to evaluate the early bone
involvement
 In case of necessary tooth extraction (see Table 3)
2. Thorough oral examination
 Signs
-Bony exposure
-Dental forcations exposure
-Oral/cutaneous fistulas
-Local or general swellings of the soft intraoral tissues
-Mobility of teeth that were stable in the preceding
inspection
-Sudden change in the health of periodontal or mucosal
tissues
Symptoms
-Undiagnosed oral pain
-Dysesthesias (e.g. numbness, feeling of a heavy jaw)
3. Achievement and/or maintenance of optimal periodontal
and dental health
 To avoid procedures that involve direct osseous
 To avoid the use of vasoconstrictor associated with local
anesthetics
 To eliminate the local risk factors (e.g. sharp edges of
dental crowns, inadequate dental prosthesis, inadequate
conservative restorative treatments)
 To examine patients with full or partial dentures for areas
of mucosal trauma, especially along the lingual flange
region (i.e. mylohyoid ridge) and where palatal and
lingual tori and bony exostoses are represented. To settle if
required.
 To make stable teeth with grade 1 or 2 of dental mobility
 To make conservative restorative and prosthesis treatments.
Nonrestorable teeth may be treated by removal of the
crown and endodontic treatment of the remaining roots.
No surgical treatment is indicated.
Table 2. Pharmacological therapy
Antibacterial Initial dose Maintenance dose
FIRST RATE
Penicillin 500 mg 3-4 times/
die for 10 days
500 mg every 12 h
Amoxicillin 500 mg 3-4 times/
die for 10 days
500 mg every 12 h
IN CASE OF PENICILLIN
ALLERGY
Clindamicin 150-300 mg 4 times/die
Erythromicin 100 mg 4 times/die
Azithromycin 400 mg 4 times/die
NON-RESPONSIVE
PATIENTS OR IN CASE
OF SEVERE
SIMPTOMATOLOGY
(IN ADDITION TO THE
PREVIOUS ONE)
Metronidazole 250-500 mg 3 times/
die for 14 days
IN CASE OF SEVERE
INFECTION
Ampicillin 1 gr 4 times/die
Clavulanic acid 500 mg 4 times/die
Metronidazole 500 mg 3 times/die
IN CASE OF PENICILLIN
ALLERGY
Ciprofloxacine + 500 mg 2 times/die
Metronidazole 500 mg 3 times/die
Erythromicin + 400 mg 3 times/die
Metronidazole 500 mg 3 times/die
Antifungal (when required)
On the basis of
susceptibility test
Antiviral (when required)
Acyclovir 400 mg 2 times/die
Valacyclovir 500 mg-2 gr 2 times/die
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4. Achievement and/or maintenance of a good oral hygiene
 Over-gingival scaling
 Instruction to oral self-hygiene
 Prescription of antiseptic rinses, such as chlorhexidine 0.12%
 Local application of fluorine
 Motivation for the importance of good dental hygiene
5. Patient education and reassurance about BRONJ
 Delivery of informative papers (e.g. letter to dentistry,
information for the patients)
 Information against every elective dental or surgical
procedures involving osseous injury
 Instruction to report every early symptom or clinical sign
(e.g. pain, swelling)
 Education to clinical and X-ray follow-up, with frequency
depending on the number of concomitant risk factors and
general dental health
Issue 3: dental management of patients before treatment
with BF
1. Thorough examination of hard and soft intraoral tissues
2. X-ray of jaws to evaluate the general oral status
3. Achievement of optimal periodontal and dental health
 Extraction of teeth with partial inclusion (only mucosal
inclusion, not bone inclusion) and of teeth with a poor
prognosis (e.g. teeth with serious periodontal disease,
nonrestorable teeth or unsalvageable with prosthesis)
 Extraction, in the children, of deciduous teeth with a certain
grade of mobility
 Etiological periodontal therapy and stabilization of teeth with
grade 1 or 2 of dental mobility
 Endodontic treatment of teeth with chronic periodontal
lesions
 Conservative restorative and prosthesis treatments, when
necessary
 Patients with full or partial dentures should be examined for
areas of mucosal trauma, especially along the lingual flange
region
 Elimination of local risk factors (e.g. sharp edges of dental
crowns, inadequate dental prosthesis, inadequate
conservative restorative treatments)
4. Achievement of a good oral hygiene
 Scaling and root planning
 Instruction to oral self-hygiene
 Prescription of antiseptic rinses, such as chlorhexidine 0.12%
 Local application of fluorine
 Motivation of patients regarding the importance of good
dental hygiene
5. Valuation of risks/benefits to delay the BF therapy
 Initiation of bisphosphonate therapy should be delayed until
periodontal and dental health is optimized. In order to get
clinical and radiographic healing, all invasive dental
procedures should be completed at least 3–4 weeks before
starting BF therapy
 Collaboration among treating physician, oncologist, dentist
and other specialists involved in the care of the patient.
6. Patient education and reassurance about BRONJ
 Delivery of informative papers (e.g. letter to dentistry,
information for the patients)
 Instructions to avoid every elective dental or surgical
procedures involving osseous injury during the treatment
with BF and at least 5 years after the cessation of
bisphosphonate therapy
 Instructions to report every early symptom or clinical sign
(e.g. pain, swelling)
 Education to periodic clinical and radiographic follow-up,
with frequency depending on the number of concomitant
risk factors and general dental health.
Issue 4: diagnosis of BRONJ vs metastatic jaw lesions in cancer
patients
It appears that one of the issues requiring to be further
addressed are challenges in suspecting and diagnosing
metastatic jaw lesions in cancer patients affected by BRONJ due
to overlapping clinical and/or radiological appearance. In fact,
considering the nature of tumors that generally affect patients
requiring bisphosphonates administration and developing jaw
osteonecrosis, the occurrence of jawbone metastases is an
expectable event. Thus, in a correct diagnostic process it should
be always kept in mind, suspected and excluded. This is
Table 3. Protocol in case of not postponed tooth extractions in patients receiving IV BF
Discontinuation of BF from 1 to 3 months before and after dento-alveolar surgery, till a complete healing of tissue1
Broad-spectrum antibiotic therapy 5 days before and 20 days after tooth extraction, until a complete healing of treated tissues occurs, in combination
with topical applications of chlorexidine gluconate
LLLT both during intra-surgical phase and 1 week after surgical treatment. Five topical applications for 1 minute should be performed. At least three
periodic meetings are necessary. The LLLT improve tissue regeneration and decrease the bacterial colonization in the site of surgical procedure.
1Currently, there is no published evidence to support or oppose discontinuation therapy of BF (both IV and per os) before required dentoalveolar surgery.
However, the removal of the anti-angiogenic effects of the drug on the soft tissues and periosteum may play an important role in a better vascularization and
a more rapid healing after surgical treatment.
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particularly true at the time of BRONJ onset, when this clinical
condition can be correctly diagnosed ruling out metastatic
infiltration from the underlying malignancy. However, clinical
picture cannot provide any useful parameter; imaging
techniques lack specificity and radiologic appearance of
BRONJ can be quite variable ranging from osteolytic to
osteosclerotic changes, so its differentiation from a metastasis
may be very difficult. The only way to accurately identify and
exclude metastatic lesions remains histopathological evaluation;
it requires biopsy execution, but if we consider when and where
carry out to a biopsy many issues remain unsolved. Surgical
procedures may lead to worsening or progression of the disease,
so, according to current clinical guidelines it is advised a
conservative approach and it is recommended that biopsies of
the exposed bone should be carried out only whenever metastatic
bone disease is suspected. However, we have neither clinical nor
radiological signs suggestive of cancer infiltration, thus a strict
application of current guidelines might restrict biopsy execution
limiting the possibility to rule out jaw metastasis; consequently,
the relevance to the patient prognosis of such a differential
diagnosis underlines the current contradiction and the need for
revising clinical guidelines regarding both biopsy schedule and
site selection. Under the latter point of view, the exposed
portion of the diseased jawbone could appear as the most
convenient site since current guidelines recommend reduction
of traumas to soft tissues. However, it is mainly constituted by
necrotic tissue, so for the results to be reliable it might be better
shifting toward margins of exposed bone. Unfortunately, by
now, we have no answer and clinical behavior remains case
sensitive on the basis of personal judgment.
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